ES8802440A1 - Un metodo para preparar una particula que puede ser empleada como vacuna contra la infeccion por hepatitis b - Google Patents

Un metodo para preparar una particula que puede ser empleada como vacuna contra la infeccion por hepatitis b

Info

Publication number
ES8802440A1
ES8802440A1 ES553953A ES553953A ES8802440A1 ES 8802440 A1 ES8802440 A1 ES 8802440A1 ES 553953 A ES553953 A ES 553953A ES 553953 A ES553953 A ES 553953A ES 8802440 A1 ES8802440 A1 ES 8802440A1
Authority
ES
Spain
Prior art keywords
hepatitis
cell lines
vaccines
diagnostics
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES553953A
Other languages
English (en)
Other versions
ES553953A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endotronics Inc
Original Assignee
Endotronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endotronics Inc filed Critical Endotronics Inc
Publication of ES553953A0 publication Critical patent/ES553953A0/es
Publication of ES8802440A1 publication Critical patent/ES8802440A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PARTICULA COMPRENDE PROTEINAS CODIFICADAS POR LA REGION CODIFICADORA DE PROTEINAS PRES1-PRES2-S, DONDE PRES1, PRES2 Y S SON REGIONES POLIPEPTIDICAS DE VIRUS DE LA HEPATITIS B, Y SE OBTIENE: 1) TRANSFECTANDO UNA CELULA ENCARIOTICA CON UN VECTOR DE ADN RECOMBINANTE QUE COMPRENDE UNA SECUENCIA DE ADN QUE CONTIENE LA REGION CODIFICADORA PRES1-PRES2-S Y EL PROMOTOR DEL GEN DE METALOTIONEINA (COMO SUPLEMENTO O EN SUSTITUCION DEL PROMOTOR NATURAL) Y QUE INCLUYE UN MARCADOR DE SELECCION; 2) CULTIVANDO LA CELULA HOSPEDANTE ENCARIOTICA TRANSFECTADA AÑADIENDO AL MEDIO METALES PESADOS U HORMONAS ENTEROIDES PARA INDUCIR AL PROMOTOR DEL GEN DE METALOTIONEINA DE FORMA QUE LA PARTICULA SE EXPRESE; Y 3) AISLANDO LA PARTICULA DE UN LISANDO DE METILO DE LA CELULA HOSPEDANTE.
ES553953A 1985-04-15 1986-04-14 Un metodo para preparar una particula que puede ser empleada como vacuna contra la infeccion por hepatitis b Expired ES8802440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP85104521 1985-04-15

Publications (2)

Publication Number Publication Date
ES553953A0 ES553953A0 (es) 1988-06-01
ES8802440A1 true ES8802440A1 (es) 1988-06-01

Family

ID=8193449

Family Applications (1)

Application Number Title Priority Date Filing Date
ES553953A Expired ES8802440A1 (es) 1985-04-15 1986-04-14 Un metodo para preparar una particula que puede ser empleada como vacuna contra la infeccion por hepatitis b

Country Status (14)

Country Link
EP (2) EP0198474B1 (es)
JP (1) JPS6255088A (es)
CN (1) CN86102640A (es)
AP (1) AP8600035A0 (es)
AT (1) ATE139795T1 (es)
DE (1) DE3650536T2 (es)
ES (1) ES8802440A1 (es)
FI (1) FI861417A0 (es)
HK (1) HK1003794A1 (es)
IE (1) IE75355B1 (es)
IL (1) IL78472A (es)
SG (1) SG43220A1 (es)
YU (1) YU60986A (es)
ZA (1) ZA862797B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
JPS62236493A (ja) * 1986-04-08 1987-10-16 Green Cross Corp:The ＨＢウイルスのＰｒｅ　Ｓ領域を含むＨＢｓＡｇの製造方法
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
EP0288198A3 (en) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Production of peptide
ES2094720T3 (es) * 1987-05-01 1997-02-01 Gen Hospital Corp Implantacion transcariotica.
EP0304578B1 (en) * 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
ATE207535T1 (de) * 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
AU619753B2 (en) * 1987-06-22 1992-02-06 Medeva Holdings B.V. Hepatitis b surface antigen vaccine
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
EP0328123A1 (en) * 1988-02-09 1989-08-16 Eugene Tech International, Inc. Heterogeneous, pre-S rich hepatitis B surface antigen
US6306625B1 (en) 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
KR0148119B1 (ko) * 1989-02-07 1998-08-17 심 파쓰 B형 간염백신의 제조방법 및 정제법
JP2957195B2 (ja) * 1989-05-17 1999-10-04 株式会社シノテスト Ｂ型肝炎ウイルス抗体検出システム
US5091300A (en) * 1989-08-03 1992-02-25 Merck & Co., Inc. Radio-immuno assay for hepatitis b virus pres2 antibodies
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
AU3269793A (en) * 1991-12-27 1993-07-28 Gensci Limited Method for obtaining recombinant surface antigen of hepatitis B, antigen and vaccine based on it
PT835663E (pt) 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
DK0672136T3 (da) * 1992-07-08 2000-08-21 Innogenetics Nv Polypeptider, der er afledt fra endonexin 2 og har hepatitis B virus-receptoraktivitet, og deres anvendelse i diagnostiske
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
CN1059927C (zh) * 1994-03-10 2000-12-27 中国科学院上海生物化学研究所 羧端带有前表面抗原1抗原决定簇的乙肝表面抗原融合基因及其编码蛋白
US6100043A (en) * 1995-08-04 2000-08-08 The Perkin-Elmer Corporation Recombinant clone selection system
US5843656A (en) * 1995-08-07 1998-12-01 The Perkin-Elmer Corporation Recombinant clone selection system
WO1997006265A2 (en) * 1995-08-07 1997-02-20 The Perkin-Elmer Corporation Recombinant clone selection system
CN1067721C (zh) * 1996-07-04 2001-06-27 中国科学院上海生物化学研究所 含前表面抗原1和2免疫决定簇的乙肝表面抗原
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US6583279B1 (en) 2001-01-26 2003-06-24 Becton, Dickinson And Company Sequences and methods for detection of hepatitis B virus
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MX2009002560A (es) 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TR201807756T4 (tr) 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN104363892A (zh) 2012-02-07 2015-02-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
CN109562057A (zh) 2016-05-16 2019-04-02 传染病研究所 聚乙二醇化脂质体和使用方法
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing a TLR agonist and methods of use
BR112018074352B1 (pt) 2016-06-01 2021-11-30 Infectious Disease Research Institute Partículas de nanoalume contendo um agente de dimensionamento
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
BR112020021271A2 (pt) 2018-04-17 2021-01-26 Celldex Therapeutics, Inc. construtos bispecíficos e anticorpos anti- cd27 e anti-pd-l1
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
CN111961664A (zh) * 2020-09-08 2020-11-20 武汉中投汉嘉科技有限公司 一种核酸提取液
AU2022253269A1 (en) 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES487106A0 (es) * 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
WO1983001783A1 (en) * 1981-11-23 1983-05-26 University Patents Inc Control of dna sequence transcription
CA1224168A (en) * 1982-12-23 1987-07-14 Dean H. Hamer Human growth hormone produced by recombinant dna in mouse cells
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues

Also Published As

Publication number Publication date
CN86102640A (zh) 1987-04-08
ATE139795T1 (de) 1996-07-15
ES553953A0 (es) 1988-06-01
HK1003794A1 (en) 1998-11-06
IE75355B1 (en) 1997-08-27
EP0719863A1 (en) 1996-07-03
AP8600035A0 (en) 1987-10-14
JPS6255088A (ja) 1987-03-10
FI861417A0 (fi) 1986-04-01
EP0198474B1 (en) 1996-06-26
EP0198474A1 (en) 1986-10-22
DE3650536T2 (de) 1997-02-27
DE3650536D1 (de) 1996-08-01
SG43220A1 (en) 1997-10-17
ZA862797B (en) 1988-04-27
IL78472A0 (en) 1986-08-31
IL78472A (en) 2004-08-31
IE860965L (en) 1986-10-15
YU60986A (en) 1988-10-31

Similar Documents

Publication Publication Date Title
AP8600035A0 (en) Hepatitis B surface antigen formed by recombinant DNA Techniques, vaccines, diagnostics, cell lines and methods of forming same.
IL87255A0 (en) Dna constructs containing a kluyveromyces alphafactor leader sequence for directing secretion of heterologous polypeptides
ES2009906A6 (es) Procedimiento de preparacion de transformantes bacterianos.
AU7165287A (en) DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
ZA822855B (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
DE3377363D1 (en) Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
NZ503343A (en) Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
ATA392082A (de) Verfahren und vorrichtung zum handhaben von gegenstaenden mittels kontinuierlich bewegter arbeitsmittel
IE820069L (en) Recombinant dna encoding a polypeptide
IL68366A (en) Process for expressing a gene encoding a protein comprising the enzymatic portion of human urokinase in a microorganism or cell culture
ATE386101T1 (de) Expressionsplasmide, durch einen osmb promoter reguliert
ES8600939A1 (es) Un procedimiento para preparar una vacuna para el virus de la hepatitis b
EP0228036A3 (en) Method for producing selected polypeptides in virally infected insect cells and polypeptides isolated therefrom
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
ES8506194A1 (es) Polipeptido de interferon- humano
EP0149241A3 (en) Dna base sequence containing regions involved in the production and secretion of a protein, recombinant dna including the whole or a part of the dna base sequence, and method of producing proteins by use of the recombinant dna
EP0146903A3 (en) Production of a vector encoding a novel hybrid interferon species
FI861559A (fi) Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
EP0254315A3 (en) Method for producing peptides
IL85759A0 (en) The cloning of malaria-specific dna sequences,isolation of the gene for the 140 kd protein
EP0183272A3 (en) Vector capable of efficient gene expression and utilization of such vector
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ